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A B S T R A C T
Purpose: The ketogenic diet (KD) has been used as an alternative to antiepileptic drugs (AEDs) for
patients with refractory epilepsy. Lennox–Gastaut syndrome (LGS) belongs to the group of epileptic
encephalopathies that often prove refractory to AED treatment.
In this prospective study we assess the efﬁcacy and tolerability of the KD in patients with LGS.
Methods: Between March 1, 1990 and April 1, 2013, 61 patients who met diagnostic criteria of LGS were
seen at our department. Twenty of them were placed on the KD and followed for a minimum of 16
months.
Results: The children had previously received a mean of 6.5 different AEDs and were on a mean of 2.5
AEDs when the diet was started. Eighteen months after initiating the diet, ﬁfteen of the initial patients
(75%) remained on the diet; three patients (15%) were seizure free, three (15%) had a 75–99% decrease in
seizures, two (10%) had a 50–74% decrease in seizures, and the remaining seven children (35%) had a
<50% decrease in seizures. Three seizure-free patients were tapered off the diet after remaining seizure
free. In the three patients who had a 75–99% decrease in seizures AEDs were reduced.
Conclusion: The KD is an effective and well-tolerated treatment option for patients with LGS, not only for
those with cryptogenic, but also for those with structural LGS. The diet should be considered early in the
course of this syndrome.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The ketogenic diet (KD) is a high-fat, low-carbohydrate, and
adequate-protein diet. It is an established, effective non-pharma-
cological treatment that has been used as an alternative in the
management of refractory epilepsy since the early 1920s.1–8 The
KD is now considered a safe and effective optional therapy not only
for children but also for adults with intractable epilepsy.9,10
Interest in the diet has been increasing despite the introduction of
a number of new antiepileptic drugs.
Although large series of patients have been reported, until
recently there were few controlled-trial data.1,3,9,11–13 A recent
randomized controlled trial supports its use in children with
treatment-intractable epilepsy.7 After three months, 28 patients
(38%) of the diet group had a greater than 50% seizure reduction
compared with four (6%) controls, and ﬁve children (7%) in the diet* Corresponding author at: Neurologı´a, Hospital de Pediatrı´a ‘‘Prof Dr Juan P
Garrahan’’, Combate de los Pozos 1881. C.P. 1245, Buenos Aires, Argentina. Tel.: +54
11 4943 6116; fax: +54 11 4943 6116.
E-mail address: rhcaraballo@arnet.com.ar (R.H. Caraballo).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights regroup had a greater than 90% seizure reduction compared with no
controls.7 A randomized trial of classical and medium-chain
triglyceride ketogenic diets in the treatment of childhood epilepsy
has shown that both diets are comparable in efﬁcacy and
tolerability. Clearly, these two ways of formulating the diet have
their place in the treatment of childhood epilepsy.8 It has been
suggested that the diet might be beneﬁcial for seizure control in
speciﬁc epileptic syndromes.9–12,14–17 The KD is effective in all
types of epileptic seizures.9–12,14–16
A wide range of hypotheses has been proposed to explain the
efﬁcacy of the KD.18–20 Different clinical studies and animal
experiments have been conducted in an effort to elucidate the
mechanisms of the KD.19,20 One hypothesis is that ketone bodies
have anticonvulsant activity similar to antiepileptic drugs. In an
experimental animal study, ketone bodies increased the inhibition
mechanisms in the hippocampal dentate gyrus.18–20 Acetone may
also exert an anticonvulsant effect. A brain ketone may be elevated
by the KD.10,18–20 Alternative mechanisms for the action of the KD
are the direct action of aceto acetate or b-hydroxy-butyrate, and
changes in the source or utilization of energy within the brain, an
increase in brain gamma-aminobutyric acid, and the potentialserved.
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indicated as antiepileptic mediators.19,20
Recent reports of series of patients after one year on the diet
show an overall efﬁcacy ranging from 15 to 50% of patients having
a >50% reduction in seizures.2–8
Lennox–Gastaut syndrome (LGS) is now classiﬁed among the
epileptic encephalopathies,21,22 with a high seizure frequency and
refractoriness to antiepileptic drugs (AEDs). LGS is characterized
by a triad of symptoms: (1) epileptic seizures: axial tonic, atonic,
and atypical absences, (2) EEG abnormalities: bursts of diffuse slow
spikes and waves during wakefulness and bursts of diffuse fast
rhythmic waves and slow polyspikes and generalized fast rhythms
at about 10 Hz during sleep, and (3) a slowing of intellectual
growth and associated personality disorders.23 The etiological
spectrum is broad, including structural, congenital or acquired,
metabolic, infectious, and other causes. Cryptogenic cases of LGS
have also been recognized.23 LGS may evolve from West syndrome
or from unspeciﬁed epilepsies, or it may represent the ﬁrst seizure
manifestation. Approximately one-third of patients with a
structural cause have a history of spasms occurring in infancy
and early childhood. Seizures begin before the age of 8 years, with a
peak between 3 and 5 years. Onset after the age of 10 years is rare.
In this prospective study, we evaluate the efﬁcacy and
tolerability of the KD in patients who met the diagnostic criteria
of LGS.
2. Materials and methods
Between March 1, 1990 and August 31, 2013, 61 patients who
met the diagnostic criteria of LGS were seen at our center. Twelve
patients (19.6%) had cryptogenic and the remaining 49 patients
(80.4%) had structural LGS. Twenty of these 61 patients were
placed on the KD using the Hopkins protocol1 and followed for a
minimum period of 16 months. Thirty-ﬁve patients with refractory
seizures were not offered the KD as they came from families who
were considered not to be prepared to follow the diet, from
families with a low socioeconomic level, and/or were adolescents.
Six patients with LGS responded well to AEDs.Table 1
The electroclinical features, treatment, and evolution of the patients before starting th
Patients Age at onset
(years)
Seizure types Seizure
frequency
Status epilepti
1 3 *TS, *AA, GTCS Daily – 
2 3.5 *TS, AA, FS, ES Daily AA status 
3 4.5 *AA, TS, MS, GTCS Daily Tonic status 
4 4 *TS, *AA, GTCS Daily – 
5 4 *TS, *AA, FS Daily Tonic status 
6 4.5 *TS, AA, AS, FS Daily AA status 
7 9 *AA, *TS, ES, FS Daily AA and Tonic 
8 3.5 *TS, *AA, AS, GTCS Daily – 
9 5 *AA, TS, FS, MS Daily AA and tonic s
10 5 *TS, *AT, MS, GTCS. Daily Myoclonic stat
11 7 * TS, *AA, AS, GTCS Daily Atonic status 
12 2.5 *AA, *TS, FS Daily Tonic status an
13 3 *TS, *AA, AS, Daily – 
14 3.5 *AA, *AS, FS, Daily – 
15 3 *TS, AS, ES, FS Daily Tonic status 
16 4 *TS, AT, MS, GTCS Daily Myoclonic and
17 2 *AA, *TS, FS, ES Daily AA and ES stat
18 3 *TS, GTCS, FS, MS Daily – 
19 4.5 *TS, AA, GTCS, FS Daily Tonic status 
20 2 *AA, TS, FS Daily – 
Abbreviations: AA: atypical absences, TS: tonic seizures, AS: atonic seizures, MS: myocl
diffuse fast rythm paroxysms, SSW: slow spikes-waves, GPWD: generalized polyspike-an
* Most frequent seizure types.Frequency of the seizures was registered using daily seizure
calendars kept by the parents. Electroencephalograms during
wakefulness and sleep were performed at least three months
before starting, while on, and after discontinuing the KD. All
patients underwent intermittent photic stimulation (IPS). Baseline
blood tests and lipid proﬁles were also obtained. Serum
bicarbonate levels were measured in all patients.
Children started fasting in the hospital for 36–48 h and were
then gradually initiated on the classic KD (Johns Hopkins protocol).
Children were begun on a 4:1 ratio (fat:protein plus carbohydrate)
and stayed in hospital for another four days for close monitoring.
During this period parents were taught about the diet. They were
asked to keep the child on the diet for at least two months to
regulate the diet for optimal tolerance and seizure control. The
ratio of the diet was progressively modiﬁed as needed to maintain
80–160 mg/dl urinary ketosis, and to avoid weight loss. Adverse
events and reasons for diet discontinuation were recorded, as were
changes in medication.
3. Results
Sixty-one children with a diagnosis of LGS were followed for 2–
20 years. Of these children, 20 (13 boys and 7 girls) were placed on
the KD as add-on to the use of one to three AEDs. Ages at initiation
of the KD were between 6 and 12 years (mean 7.5 years).
All patients had more than one type of seizure before starting
the diet: Three patients had two types, 14 had three types, and two
had more than three types of seizures. Patients with tonic and
absence seizures had an average of 93 and 86 episodes a month,
respectively. Patients with atonic seizures had an average of 51,
those with generalized tonic–clonic seizures had an average of 35,
those with myoclonias had an average of 30, those with epileptic
spasms had an average of 20, and those with focal seizures had an
average of 26 episodes a month.
The children had previously received a mean of 6.5 different
AEDs and were on a mean of 3.5 AEDs when the diet was begun.
Six cases of 20 were cryptogenic. Fourteen patients had
structural lesions, ﬁve of them had an acquired etiology, foure KD.
cus EEG abnormalities AEDs MR
DFRP, GPWD, SSW VPA-CLB-TPM Moderate
Asymmetric DFRP and
SSW, FS
VPA-CLB-LTG Moderate
DFRP, SSW, GPWD CLB-TPM-LVT Severe
DFRP, SSW. GPWD CLB-TPM-VPA Normal
DFRP, SSW, MS VPA-CLB-TPM Moderate
DFRP, SSW, FS LTG-CLB-LVT Moderate
STATUS DFRP, SSW, Burst suppression VPA-TPM-LTG Severe
DFRP, SSW, GPWS VPA-LVT-TPM Normal
tatus- Asymmetric SSW and
DFRP
TPM-LTG Mild
us DFRP, Asymmetric SSW,
GPWD,
VPA-LTG Severe
Symmetric SSW LTG-CLB Moderate
d GTCS DFRP, SSW, FS TPM-LTG Severe
DFRP, SSW, GPWD VPA-TPM Mild
SSW, MS TPM-CLB Moderate
DFRP, GPWD, MS VPA-CLB-TPM Severe
 AA status DFRP, FS, GPWS TPM-LVT-CLB Moderate
us DFRP, SSW, MS VPA-CLB-TPM Moderate
DFRP, MS LTG-TPM-LVT Moderate
DFRP,SSW, MS VPA-CBL-LVT Severe
DFRP, SSW, FS, GSWD LVT-TPM Moderate
onic seizures, GTCS: generalized tonic-clonic seizures, ES: epileptic spasms; DFRP:
d-wave discharges, MS: multifocal spikes, FS: focal spikes. MR: mental retardation.
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sclerosis, two had down syndrome, and the remaining patient had
vascular disease. Considering efﬁcacy of the diet, no differences
were found according to etiology.
Table 1 shows the electroclinical features, treatment, and
evolution of the patients before diet initiation and in Table 2 while
on the KD.
3.1. Duration on the diet
One of the 15 original children stayed on the diet for 18 months,
three children remained on the diet for 2 years, six children for 3
years, one for 5 years, three children remained on the diet for 6
years, and one child for 8 years.
3.2. Efﬁcacy of the diet
Eighteen months after initiating the diet, ﬁfteen of the initial
patients (75.5%) remained on the diet. Three patients (15%) were
seizure free, three children (15%) had a 75–99% decrease in
seizures, two patients (10%) had a 50–74% decrease in seizures, and
the remaining seven children (35%) had a less than 50% seizure
reduction. All three patients that became seizure free had
cryptogenic LGS; the remaining patients who continued on theTable 2
The electroclinical features, treatment, and evolution of the patients while on the KD a
Patients Age at initiation
(years)
Seizure
frequency
EEG abnormalities
at the last follow-up
AEDs 
1
Structural
6 Daily DFRP, SSW, GPWD VPA-C
2
Structural
7 Daily DFRP, SSW, FS. VPA, L
3
Structural
8 Daily DFRP, SSW, GPWD CLB-TP
4
Cryptogenic
7 Seizure-free Normal – 
5
Structural
7 Sporadic GPDW TPM 
6
Structural
8 Daily DFRP, SSW, GPWD,
FS
CLB, LV
7
Structural
12 Weekly DFRP, GPWD VPA-LT
8
Cryptogenic
6.5 Seizure-free Normal – 
9
Structural
9 Sporadic GPWD CLB, LV
10
Structural
9 Daily DFRP, SSW, GPWD VPA-LT
11
Cryptogenic
10 Monthly Occasional GPWD LTG, L
12
Structural
6.5 Daily SSW, GPWD, FS TPM, L
13
Cryptogenic
6 Seizure-free GPWD VPA 
14
Structural
7 Bi-monthly SSW TPM, C
15
Structural
6 Daily DFRP, MS TPM, C
16
Cryptogenic
6 DFRP, SSW, GPWD TPM, L
17
Structural
7 Weekly SSW, GPWD, MS VPA, C
18
Structural
6 Weekly DFRP, SSW, MS LTG, T
19
Structural
7 Daily LVT, V
20
Cryptogenic
7 Weekly TPM, L
Abbreviations: MS: myoclonic seizures, DFRP: diffuse fast rythm paroxysms, SSW: slow
spikes, FS: focal spikes.diet had structural LGS, except one cryptogenic patient with a 75–
99% and another with a 50–74% decrease in seizures, respectively.
Thus, 18 months after starting the diet, eight patients (40%) had
achieved a more than 50% decrease of seizures. Two patients have
been off the diet for several years and remain seizure free, one of
whom does not receive any AEDs. Three patients have sporadic
seizures, but AEDs were reduced to one. Three patients have
monthly seizures, four have weekly seizures, and the remaining
patients have daily seizures. In our series of patients, the KD was
effective mainly in tonic, atonic, myoclonic-atonic seizures and
epileptic spasms. We also observed that the diet worked in atypical
absences, generalized tonic–clonic seizures, and less frequently in
focal seizures. One patient who had a less than 50% decrease in
seizures, combination with vagus nerve stimulation (VNS) was
used, signiﬁcantly improving seizure control.
3.3. Reasons for discontinuing the diet, tolerability, and adverse
events
Five of the 20 children (25%) who initiated the diet discontinued
within the ﬁrst year. In three, the reason given for discontinuing
the diet was lack of effectiveness. Two of these children
discontinued after between 1 and 2 months and one discontinued
3 months after starting the diet.nd at the last follow-up.
Side effects Duration
of KD
Follow-up
after KD
discontinuation
Results
LB – 1 month No response
TG Vomiting 23 days Discont. adv.
effects
M – 2 months No response
– 3 years 9 years seizure
free
Seizure-free
– 3 years 75–99%
T, ZNS – 3 months No response
G – 6 years 50–74%
– 2 years 3.5 years seizure
free
Seizure free
T, TPM – 6 years 75–99%
G Vomiting,
hypoglycemia
4 months Discont. adv.
effects
VT – 18 months 50–74%
VT 8 years 50–74%
2 years 2 years Seizure free
LB 5 years 75–99%
BL 3 years <50%
VT 3 years <50%
LB 6 years <50%
PM 3 years <50%
PA 2 years <50%
VT 3 years <50%
 spikes-waves, GPWD: generalized polyspike-and-wave discharges, MS: multifocal
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hypoglycemia in one, was the reason for discontinuing the diet one
month after the initiation. Fifteen patients who remained on the
diet for more than one year did not develop severe complications,
such as high levels of uric acid, kidney stones, severe acidosis,
lethargy, or hypoglycemia.
3.4. Electroencephalographic changes
In all patients who followed the KD with good response, EEG
recordings of at least 3 months before starting the KD showed very
frequent symmetric or asymmetric bilateral slow spikes and
waves, fast diffuse paroxysms, diffuse spike-and-polyspike par-
oxysms, and focal and multifocal spikes. Eighteen months after
initiating the diet, the EEG abnormalities had improved in all of
them. The EEG recording was normal in two of three patients who
became seizure free. In the remaining seizure-free patient, and in
three patients who achieved a 75–99% seizure reduction, the EEG
recording showed infrequent generalized spikes and waves and
polyspikes and waves, and sporadic diffuse fast paroxysms. In both
patients who achieved a 50–74% seizure decrease, EEG abnormali-
ties during sleep improved between 50% and 70%. In the remaining
seven patients with a seizure reduction of less than 50%, the EEG
abnormalities during sleep improved between 25% and 50%. The
changes of abnormalities were determined according to the
quantity of paroxysmal discharges on the sleep EEG recording.
The EEG abnormalities remained unchanged in the patients in
whom the diet proved to be ineffective and in the patients who did
not tolerate the diet.
3.5. Decreasing and discontinuing medications
Medications were decreased and discontinued non-systemati-
cally with the aim of the patient becoming medication free.
Two of three patients who became seizure free had a
cryptogenic or unknown etiology. They do not receive any AEDs
and have a normal IQ and EEG recording after 3.5 and 9 years of
follow-up, respectively. The remaining seizure-free patient is on
valproic acid (800 mg per day). The neuropsychological proﬁle
returned to baseline and the EEG shows sporadic generalized
polyspikes and waves after 2 years of follow-up.
4. Discussion
Our experience with the KD in 20 children with LGS shows an
overall good response in terms of seizure frequency and
tolerability, not only in the cryptogenic but also in the structural
group.
The ketogenic diet has been recommended by several authors
for children with severe epilepsy, amongst which LGS.10,14,15
Freeman et al.24 have studied the effectiveness of the KD versus an
inactivated KD with glucose intake in a series of 20 LGS subjects.
Seizure frequency decreased signiﬁcantly and rapidly in the KD
group.
Interictal epileptiform abnormalities improved in most of our
patients who had a seizure reduction of more than 75%. Similar
ﬁndings have been reported in the literature.25,26
The KD has been successfully used in children with a variety of
seizure types and epileptic syndromes, especially epileptic
encephalopathies including LGS,9,10,14,15,27–30 West syn-
drome11,12,29,30 epilepsy with myoclonic atonic seizures,31,32
Dravet syndrome,27,28 Landau–Kleffner syndrome,33 Tassinari
syndrome,29 and FIRES.29 Recently, Mullen et al.34 have shown
that 5% of children with epilepsy with myoclonic atonic seizures
have glucose transporter 1 deﬁciency with mutations of the SLC2A1
gene. In this entity, the KD should be introduced early in thetreatment of the disorder with potential beneﬁcial effects for
cognition as well as seizure control. In patients with cryptogenic
LGS, glucose transporter 1 deﬁciency should be ruled out.
As in our studies on the treatment of patients with Dravet
syndrome (DS)27,28 and epilepsy with myoclonic and atonic
seizures31 with the KD, no differences were found in the effect
of the diet on the seizure types.
It is interesting to note that a signiﬁcant number of patients in
our previous studies25 as well as in this study who responded well
to KD additionally received topiramate. This association may
increase the risk of kidney stones, but may also improve seizure
control.35
In this study, one patient with a less than 50% seizure reduction,
VNS was implanted with a good response. This combined therapy
between KD and VNS was considered a rational polytherapy. The
combined use of the diet and VNS appeared synergistic.36
We believe that more precise deﬁnitions of epileptic syndromes
may lead to the possibility of giving a clear prognosis in each
particular case.9,10,14,16,29
Families that are able to make the effort that treatments such as
the KD require in children have to be carefully selected so as to
reduce the number of failures. Risk families are those in whom the
parents are considered not to be able to strictly follow the diet for
different reasons, such as having numerous children or having
psychological problems. In developing countries, caregivers may
not have the ﬁnancial means to confront the extra cost posed by
the diet.
5. Conclusion
The KD is a promising therapy for LGS, with over half of the
children showing a >50% reduction in seizures, and 20% achieving
seizure freedom. It should be considered early in the course of the
syndrome, and not as a last resort. The patients that responded
well to the diet did not further mentally deteriorate. The youngest
child on the KD in our series of patients with LGS was 5 years old.
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